Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage

Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage

Continuous erythropoietin receptor activator (CERA) seems to maintain a stable hemoglobin (Hb) level because its half-life is longer than darbepoetin α (DA). Twenty chronic kidney disease (CKD) patients at the pre-dialysis stage who had been administered DA for over 24 weeks were randomly assigned t...

Full description

Bibliographic Details
Main Authors:	Tetsuya Furukawa, Kazuyoshi Okada, Masanori Abe, Ritsukou Tei, Osamu Oikawa, Noriaki Maruyama, Takashi Maruyama
Format:	Article
Language:	English
Published:	MDPI AG 2015-12-01
Series:	International Journal of Molecular Sciences
Subjects:	chronic kidney disease erythropoiesis-stimulating agent darbepoetin α continuous erythropoietin receptor activator renal anemia
Online Access:	http://www.mdpi.com/1422-0067/16/12/26229

Similar Items

SEARCH OF NEW PHARMACEUTICALS ON THE BASIS OF DARBEPOETIN IN THE TREATMENT OF ISCHEMIC STROKE (REVIEW OF LITERATURE)
by: Konstantin Reznikov, et al.
Published: (2017-03-01)

New alternatives for erythropoietin therapy in chronic renal failure
by: Stoian Irina, et al.
Published: (2007-12-01)

Oral Zinc Supplementation Reduces the Erythropoietin Responsiveness Index in Patients on Hemodialysis
by: Hiroki Kobayashi, et al.
Published: (2015-05-01)

The use of darbepoetin alpha in infants
by: A. V. Shchegolev, et al.
Published: (2019-06-01)

Erythropoietin use and abuse
by: M Joseph John, et al.
Published: (2012-01-01)

Darbepoetin Use for the Treatment of Anemia in Hemodialysis Patients in Saudi Arabia
by: Shaheen Faissal, et al.
Published: (2006-01-01)

Randomized Study of Darbepoetin Alfa and Recombinant Human Erythropoietin for Treatment of Renal Anemia in Chronic Renal Failure Patients Receiving Peritoneal Dialysis
by: Wen-Yi Li, et al.
Published: (2008-11-01)

The efficacy of darbepoetin alpha in hemodialysis patients resistant to human recombinant erythropoietin (rHuEpo)
by: Hejaili Fayez
Published: (2009-01-01)

Renal Cell Protection of Erythropoietin beyond Correcting The Anemia in Chronic Kidney Disease Patients
by: Hamid Nasri
Published: (2013-01-01)

The biogenesis of erythropoietin during inflammation
by: Leng, Henry Martin John
Published: (2018)

Acai Extract Transiently Upregulates Erythropoietin by Inducing a Renal Hypoxic Condition in Mice
by: Shuichi Shibuya, et al.
Published: (2020-02-01)

Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial
by: Shubhadeep D. Sinha, et al.
Published: (2019-03-01)

Antibody-mediated pure red cell aplasia after treatment with darbepoetin-alpha postrenal transplantation
by: Badarinath Vellaboina, et al.
Published: (2019-01-01)

Pharmacoeconomic analysis of long term use of darbepoetin-α in treating chronic nephropathy-induced anemia in dialysed patients
by: Nicola Giotta, et al.
Published: (2007-06-01)

Erythropoietin Protects the Kidney by Regulating the Effect of TNF-α in L-NAME-Induced Hypertensive Rats
by: Mete Ozkurt, et al.
Published: (2018-05-01)

Erythropoietin between therapy and doping : Two sides of the same coin
by: Ostojić Ana, et al.
Published: (2016-01-01)

DETERMINATION OF DARBEPOETIN ALFA IN RABBIT PLASMA BY ELISA
by: M. V. Karlina, et al.
Published: (2019-01-01)

Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
by: Jeon I, et al.
Published: (2021-04-01)

The Neural Crest as the First Production Site of the Erythroid Growth Factor Erythropoietin
by: Ikuo Hirano, et al.
Published: (2019-06-01)

Plasma erythropoietin level and heart failure in patients undergoing peritoneal dialysis: a cross-sectional study
by: Kohsuke Terada, et al.
Published: (2021-01-01)

Protective effects of Tadalafil and darbepoetin against ischemia - reperfusion injury in a rat testicular torsion model
by: Caglar Yildirim, et al.

Erythropoietin production by the kidney and the liver in response to severe hypoxia evaluated by Western blotting with deglycosylation
by: Yukiko Yasuoka, et al.
Published: (2020-06-01)

THE STUDY OF RENOPROTECTIVE PROPERTIES OF ERYTROPOETIN DERIVATIVES ON THE KIDNEY ISCHEMIA-REPERFUSION MODEL
by: V. V. Elagin, et al.
Published: (2018-12-01)

Comparative efficacy and safety of biosimilar darbepoetin alfa in adults with anemia of chronic kidney disease
by: Prasad Apsangikar, et al.
Published: (2018-01-01)

Infantile Pyknocytosis: End-Tidal CO, %Micro-R Measurements, Next-Generation Sequencing, and Transfusion Avoidance with Darbepoetin
by: Timothy M. Bahr, et al.
Published: (2020-12-01)

Acquired pure red cell aplasia following recombinant erythropoietin (darbepoetin-alfa) therapy
by: Somanath Padhi, et al.
Published: (2020-01-01)

Different effects of granulocyte colony-stimulating factor and erythropoietin on erythropoiesis
by: Tzu-Lin Chen, et al.
Published: (2018-05-01)

How to select appropriate hemoglobin target levels on health-related quality of life and outcomes for patients with chronic kidney disease?
by: Filippo Salvati
Published: (2013-12-01)

USE OF DARBEPOETIN ALFA (ARANESP®) FOR ANEMIA TREATMENT IN CHILDREN WITH CHRONIC KIDNEY DISEASE – CLINICAL EXPERIENCE OF BULGARIAN PEDIATRIC GROUP
by: Maria Gaydarova, et al.
Published: (2017-01-01)

A pharmacist‐managed dosing algorithm for darbepoetin alfa and iron sucrose in hemodialysis patients: A randomized, controlled trial
by: Francisca Johanna van denOever, et al.
Published: (2020-08-01)

Erythropoietin, erythropoiesis, and malarial anemia : the mechanisms and implications of insufficient erythropoiesis during murine blood-stage malaria
by: Chang, Kai-Hsin, 1974-
Published: (2003)

Darbepoetin Alfa in Young Infants With Renal Failure: Single Center Experience, a Case Series and Review of the Literature
by: Anna Maria Libudzic-Nowak, et al.
Published: (2018-12-01)

LONG-ACTING ERYTHROPOETIN EFFICACY IN THE TREATMENT OF NEPHROGENIC ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT A PREDIALYSIS STAGE
by: Yu S Milovanov, et al.
Published: (2012-06-01)

A randomized crossover study of single biweekly administration of epoetin-α compared with darbepoetin-α in chronic kidney disease patients not receiving dialysis
by: Ha-Young Na, et al.
Published: (2014-12-01)

Etude du rôle de l’Erythropoïétine et des systèmes de neurotransmission dans la mise en place des réponses ventilatoires à l’hypoxie et à l’hypercapnie
by: Jeton, Florine
Published: (2016)

The development of a method for determining the biological activity of erythropoietin preparations in vitro
by: N. A. Gavrilova, et al.
Published: (2018-02-01)

Molecular Insights into the Oxygen-Sensing Pathway and Erythropoietin Expression Regulation in Erythropoiesis
by: Jana Tomc, et al.
Published: (2021-06-01)

RATIONAL SUPPORTIVE THERAPY FOR CHEMOTHERAPY INDUCED ANEMIA: A PHARMACO-ECONOMIC ANALYSIS OF ERYTHROPOIETIN THERAPY IN CANCER PATIENTS IN RUSSIAN FEDERATION
by: V. B. Larionova, et al.
Published: (2018-07-01)

Pathogenesis and therapy of anemia in oncohemathology patients with recombinant erythropoietin agents (review)
by: N. A. Romanenko
Published: (2014-07-01)

Pathogenesis and therapy of anemia in oncohemathology patients with recombinant erythropoietin agents (review)
by: N. A. Romanenko
Published: (2014-07-01)